Half A Year Study On Commercialization Of New Crown Vaccines In China And Abroad: Who Is The "King Of Gold"?

Recently, when the "delta" mutant strain wreaked havoc all over the world, leading to a new round of epidemic pandemic, Chinese and foreign new crown vaccine listed companies have successively handed over the commercialization report cards in the past six months, relying on the rapid listing of the new crown vaccine, large-scale sales, many enterprises have a greater income. With no hope of a short-term end to the new crown epidemic, many new crown vaccine enterprises have raised their sales expectations for the whole year, and at the same time, the follow-up focus has been on strengthening the research on the protection of vaccines and vaccines against mutants.

On the 10th, biontech released its second quarter results for 2021. It has been disclosed that the new crown vaccine bnt162b2 jointly developed by the company and Pfizer has been used in more than 100 countries and regions around the world. The company not only announced the latest research and development plan for the currently popular delta variant, but also disclosed that it had carried out a clinical trial to test the safety and immunogenicity of the third booster vaccine six months after the second dose of the new crown vaccine.

In recent days, China's new crown vaccine enterprises have also released new research progress: Kangtai biological said that it had successfully isolated a number of "delta" mutant monoclonal strains; Kexing biological said that its new crown vaccine can help people over 70 years old to effectively resist the new coronavirus gamma mutation strain; According to the senior management of kangxinuo biology, the neutralizing antibody level in the body can be increased by about 8 times.

2021 is the first year of commercialization of the new crown vaccine. From rapid research and development, rapid approval to rapid large-scale commercialization, this progress is unprecedented in the global pharmaceutical history. Whether it is biontech, Moderna, or innovative enterprises such as China Kexing and kangxinuo, they have all realized counter attack in this wave of epidemic.

In this decisive battle related to the fate of mankind, no matter the size of enterprises, we all stand on the same running line. Whether we can finally stand out depends on luck and strength.

Of course, whether an enterprise is successful or not, the product is the ultimate touchstone, and the market has the right to speak.

Vaccines become the most profitable business and multinational pharmaceutical enterprises welcome the best-selling products

At present, four new crown vaccines are mainly used abroad, including biontech / Pfizer, Moderna, Oxford / AstraZeneca and Johnson & Johnson. Among them, Pfizer and Moderna are mainly mRNA vaccines, and AstraZeneca and Johnson & Johnson are recombinant adenovirus vector vaccines.

Among them, Pfizer mRNA vaccine and AstraZeneca recombinant adenovirus vector vaccine have been approved by more than 100 countries and regions. With the continuous spread of new coronavirus pneumonia and the rapid promotion of vaccine commercialization process, these new crown vaccine R & D companies have entered the performance realization period.

The most obvious is biontech, which works with Pfizer to produce vaccines. According to the financial report of the second quarter of 2021 released by biontech on August 10, the revenue in that quarter increased nearly 130 times year-on-year, which was much higher than the market expectation. In addition, the sales forecast of new crown vaccine in this year has also been increased to 15.9 billion euro. After the announcement of the financial report, biontech's rise expanded to about 12%, breaking its intraday high since the US IPO in 2019 to US $435.79.

In the financial report, biontech also pointed out that it had raised the sales forecast of the new crown vaccine to 15.9 billion euro this year, which was based on the 2.2 billion dose vaccine supply contract signed so far.

According to Ugur Sahin, chief executive officer and co-founder of biontech, the global delivery of the new crown vaccine produced by the company and Pfizer has exceeded the mark of 1 billion doses in just six months, and the company is expanding the supply of vaccines to more than 100 countries and regions around the world.

Similarly, the sales performance of new crown vaccine is also the biggest bright spot in Pfizer's financial report. According to Pfizer's financial report, the second quarter's revenue was 18.98 billion US dollars, up 92% year-on-year, exceeding the market's expected US $18.79 billion; Adjusted earnings per share in the second quarter were $1.07, up 73% year-on-year, exceeding market expectations of 99 cents. It is worth noting that the new crown vaccine is expected to bring Pfizer $33.5 billion in revenue this year, which is expected to become one of the best-selling drugs in Pfizer's history.

In contrast, the growth trend of AstraZeneca vaccine and Johnson & Johnson vaccine is slightly slow. On July 21, Johnson & Johnson announced the first half of 2021 financial report data, which showed that Johnson & Johnson covid-19 vaccine realized 264 million US dollars revenue for it, and the market growth was slow due to factors such as safety and mutation of disease strains. On July 29, AstraZeneca released its semi annual report, with a total revenue of 15.54 billion US dollars, a year-on-year increase of 23%. Covid-19 vaccine (vaxzevria) brought in 1.17 billion US dollars.

According to British media on August 1, Pfizer and Moderna started a new round of negotiations with the European Union on the supply price because the clinical trial data showed that the efficacy of Pfizer vaccine and Moderna vaccine was higher than that of AstraZeneca vaccine and Johnson & Johnson vaccine.

In December 2020, the new coronal vaccine of Moderna was granted emergency use authorization after Pfizer / biontech new crown vaccine, which was the second new crown vaccine approved by the United States. In the second quarter, Modena sold 199 million doses of its new mrna-1273 vaccine, with sales of $4.197 billion. A total of 302 million doses were sold in the first half of 2021, with sales of $5.930 billion.

In addition to the United States, Moderna's vaccines are authorized for emergency (or other conditional, temporary) use by health agencies in more than 50 countries / regions. The World Health Organization has included it in the emergency use list (Eul), and the regulatory authorities in the European Union and Japan have expanded its application to adolescents aged 12 and above.

Both biontech and Moderna, due to the excellent protection rate of mRNA vaccine, jointly indicate the astonishing efficiency of mRNA vaccine technology in activating the immune system, and make the two enterprises become the biggest winners in the vaccine layout market of multinational pharmaceutical enterprises.

New crown vaccine sales are considerable, domestic vaccine enterprises are growing up strongly

In the fierce competition for foreign vaccine market, domestic new crown vaccine enterprises are not idle.

According to the National Health Commission, as of August 9, 2021, 31 provinces (autonomous regions and municipalities directly under the central government) and Xinjiang production and Construction Corps have reported 1795.049 million doses of new coronavirus vaccine. With the continuous expansion of vaccination population of new coronal pneumonia vaccine in China, domestic vaccine enterprises have also made great efforts.

According to the financial report of Kangxi Nuo, in the first half of 2021, the operating revenue of Kangxi Nuo was 2-2.2 billion yuan, with a year-on-year increase of 49532.59% to 54495.85%. It is estimated that in the first half of 2021, the net profit attributable to the owners of the parent company will be RMB 900 million to RMB 1.05 billion, which will turn losses into profits, an increase of RMB 1 billion-1.15 billion compared with the same period of last year. It is estimated that the net profit deducted will be 850 million to 1 billion yuan, an increase of 966 million to 1 126 million yuan over the same period last year.

As "the first stock of vaccine in Hong Kong stock market", Kangxi Nuo benefited from the sales of new coronal pneumonia vaccine and lost money for 10 years, finally ushered in a day of turning losses into profits. The successful marketing of the new crown vaccine has an immediate effect on the performance of kangxinuo.

However, in the current Chinese and international market, there are also many competitors. It is reported that since the first recombinant new crown vaccine (CHO cell) of Zhifei biology was approved and officially launched in March this year, Anhui zhifeilong Kema biopharmaceutical Co., Ltd. has produced more than 100 million doses of vaccine. According to the previous Zhifei biological disclosure, the company will produce 500 million doses of new coronal pneumonia vaccine this year.

In addition, China biopharmaceuticals and Kexing are also key competitors of conconor. On May 24, China biopharmaceuticals released financial reports showing that the company's net profit in the first quarter was about 1.914 billion yuan, an increase of about 118.5% over the same period last year. Among them, the profits of associated companies and a joint venture company reached about 1.476 billion yuan (only about 2.493 million yuan in the same period of last year).

In the financial report telephone conference, China biopharmaceutical said that the income of the joint venture mainly came from Kexing Zhongwei. According to the data, in December 2020, China biopharmaceutical invested $515 million to Kexing, holding 15.03% of its equity. According to this calculation, the profit of 15.03% equity of China biopharmaceutical is 1.476 billion yuan, and the overall profit of Kexing in the first quarter is close to 10 billion yuan.

On the afternoon of July 12, the global alliance for vaccines and immunization (GAVI) announced on its official website that Sinopharm and Kexing bio signed pre purchase agreements with covax respectively. From July this year to the first half of next year, the two enterprises promised to supply 550 million doses of new coronavirus vaccine to the "implementation plan of new coronal pneumonia vaccine". At present, the first and second batch of new coronal vaccines of sinopharma group have been shipped.

In addition, according to the public data, Beijing Economic and Information Bureau has guaranteed the expansion of production of two new crown vaccine enterprises, namely, Kexing Zhongwei and Beijing biology, and has supplied more than 1.5 billion doses of new coronavirus vaccine to China, guaranteeing more than 90% of the national vaccination demand, and the output value has exceeded 122 billion.

Both China biopharmaceuticals and Beijing biological products belong to sinopharma group. In other words, there is no doubt that sinopharma group is still the dominant vaccine market in the whole domestic market.

China's vaccines take the road of "speed competition" and run with the world's leading pharmaceutical enterprises

The global pandemic of new crown pneumonia has reshaped the pharmaceutical industry, while Biopharmaceutical Enterprises with outstanding innovation ability try to play the role of terminator in the pandemic. Biopharmaceutical Enterprises are indispensable from the vigorous search for antiviral drugs in the early stage of the epidemic to the contention of a hundred schools of thought in vaccine research and development under various technical routes in the later stage.

Gu Jinhui, deputy director of the Department of science and education of the National Health Commission, said at the 2021 national annual meeting of pharmaceutical industry information that the new coronapneumonia vaccine, as a global public product, is of great significance to the construction of a community of shared future for mankind. Without a vaccine, the global annual costs associated with the new outbreak and its impact on the economy could reach $3.4 trillion. If only countries with vaccine development capabilities (the European Union, the United States, China, the United Kingdom, India and Russia) are vaccinated, the annual costs associated with the new outbreak and its economic impact in other countries could reach $1.23 trillion.

After the outbreak, China has chosen five technical routes to accelerate the development of new coronavirus vaccines, namely, inactivated vaccine, recombinant subunit vaccine, adenovirus vector vaccine, attenuated influenza virus vector vaccine and nucleic acid vaccine. The five technical routes adopted by China cover the main types of new coronavirus vaccines under research in the world.

According to the "global application prospect report of new crown vaccines" released by Boao Forum for Asia on July 29, as of July 16, there were 135 candidate vaccines in the world, a total of 391 vaccines in clinical trials, and a total of 20 new crown vaccines were approved for application. Among them, 7 new coronal vaccines were approved for emergency use or on the market, and 22 new coronal vaccines entered clinical trials. China has always been the first country in the global research and development of new coronal vaccines. Among the 7 approved vaccines, 5 are inactivated vaccines (Beijing Institute of biology of China, Wuhan Institute of biology, Kexing biology, Kangtai biology, Institute of medical biology, Chinese Academy of Medical Sciences), 1 recombinant adenovirus vector vaccine (kangxinuo Biology) and 1 recombinant protein vaccine (Zhifei).

"No research steps have been omitted, all research standards have not been lowered, and the safety and effectiveness of the new cap vaccine have been fully guaranteed. In accordance with the requirements of relevant emergency laws and regulations, the national drug inspection institutions and drug examination institutions have intervened in advance, carried out rolling review, pre inspection and parallel verification in accordance with the requirements of relevant emergency laws and regulations, which has greatly shortened the research and development time. On the whole, China's vaccine and the world's leading enterprises are basically in the stage of running together. " Gu Jinhui said.

In addition, according to the latest official report, China's new crown vaccine vaccination has reached nearly 1.8 billion doses, and China has also provided more than 700 million doses of vaccine to foreign countries.